ArticleCancer immunology, immunotherapy : CII2022

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.

Qiaoyun Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.